Evaluation of cardiac biomarker elevation after percutaneous coronary intervention or coronary artery bypass graft

Conditions

Patients with multivessel coronary artery disease and stable angina with formal indication for revascularization procedures Circulatory System Angina pectoris, unspecified

Boros GAB, Hueb W, Rezende PC, Rochitte CE, Nomura CH, Lima EG, de Oliveira Laterza Ribeiro M, Dallazen AR, Garcia RMR, Ramires JAF, Kalil-Filho R.

2024-07-091 citations

10.1186/s13098-024-01395-9

Long-term prognostic value of late gadolinium enhancement and periprocedural myocardial infarction after uncomplicated revascularization: MASS-V follow-up

Jaime Linhares-Filho, Whady Hueb, Eduardo Gomes Lima, Paulo Cury Rezende, Diogo Freitas Cardoso de Azevedo et al. (10 authors)

European Heart Journal - Cardiovascular Imaging2020-11-134 citations

10.1093/ehjci/jeaa328

Abnormal elevation of myocardial necrosis biomarkers after coronary artery bypass grafting without established myocardial infarction assessed by cardiac magnetic resonance.

Oikawa FTC, Hueb W, Nomura CH, Hueb AC, Villa AV, da Costa LMA, de Melo RMV, Rezende PC, Segre CAW, Garzillo CL, Lima EG, Ramires JAF, Filho RK.

2017-12-293 citations

10.1186/s13019-017-0684-3

Myocardial injury in diabetic patients with multivessel coronary artery disease after revascularization interventions.

Rezende PC, Hueb W, Rahmi RM, Scudeler TL, de Azevedo DFC, Garzillo CL, Segre CAW, Ramires JAF, Filho RK.

2017-11-212 citations

10.1186/s13098-017-0292-3

Interventions

Percutaneous coronary intervention using stents - 5 year follow-up Coronary artery bypass graft with cardiopulmonary bypass (on-pump) - 5 year follow-up Coronary artery bypass graft without cardiopulm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Stable angina 2. Multi-vessel coronary artery disease 3. Preserved left ventricular function 4. Formal indication to revascularization procedures (PCI or CABG)

Exclusion criteria

Exclusion criteria: 1. Recent myocardial infarction (=6 months) 2. Signs of manifest or suspected infections 3. Rheumatologic disease activity 4. Chronic renal failure (creatinine level >2.0mg/dL) 5. Recent (= 6 months) pulmonary embolism or venous thromboembolism 6. Does not sign the consent form 7. Contraindication for the use of glycoprotein IIb/IIIa inhibitors 8. Cardiac magnetic resonance (CMR) examination, for example, a person with a pacemaker or severe claustrophobia

Design outcomes

Primary

Measure	Time frame
Overall death in a 5-year follow-up	—

Secondary

Measure	Time frame
1. Levels of CK-MB isoenzyme and I-Troponin in association with presence of myocardial fibrosis 2. Left ventricle ejection disfunction assessed by CMR	—

Countries

Brazil

Outcome results

None listed